Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer

Comparison of the Clinical Response of Total nEoadjuvant Treatment of Two Methods of Long-term or Short-term cHemoRadiotherapy Followed by Consolidation Chemotherapy in Patients With Locally Advanced rectAl Cancer (TEHRAN) , a Randomized Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230604058384N1

Enrollment

114

Registered

2023-06-14

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer. Malignant neoplasm of rectum

Interventions

Intervention 1: Intervention group: Long-course radiation therapy with a dose of 50.4 Gy in 28 sessions along with concurrent chemotherapy with capecitabine at a dose of 825 mg/m2 and then consolidati

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Locally advanced (T3-4, N+)adenocarcinoma of rectum is located 5 to 15 cm from anal verge is located 5 to 15 cm from anal verge

Exclusion criteria

Exclusion criteria: Familial syndromes e.g. lynch Previous history of cancer Previous history of chemotherapy Recurrent disease Metastatic disease Inability to perform MRI (Claustrophobia or prosthetic valve)

Design outcomes

Primary

Measure	Time frame
Complete clinical response. Timepoint: 16 weeks from the start of treatment. Method of measurement: MRI, MR-TRG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Masoud Miratashi Yazdi

Tehran University of Medical Sciences

masoudssu@yahoo.com+98 21 8163 3626

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026